In patients with anti-PD-1/PD-L1-naive NSCLC, treatment-related adverse events (TRAEs) were observed in 85% of cases, with pruritus (38%) and hypoalbuminemia (31%) being the most common ones. This evidence concerns the gene CD274 and Hypoalbuminemia.